Fezolinetant Improves Sleep in Menopausal Women
A new phase 4 study finds the medication reduces nighttime awakenings and vasomotor symptoms for menopausal patients.
Updated on Oct. 22, 2026 in Women’s Health
Live Poll
Do you believe new non-hormonal medical treatments are effectively improving quality of life for menopausal women?
The phase 4 OPTION-VMS study shows that women taking 45 mg of fezolinetant experienced significant improvements in sleep and vasomotor symptoms. Participants saw measurable results as early as four weeks into the treatment.
Why it matters
By blocking neurokinin B binding in the brain, fezolinetant helps regulate the body's temperature control center to reduce hot flashes and sleep disturbances. This provides a targeted approach for the 40% to 60% of menopausal women who report frequent sleep issues.
The OPTION-VMS study demonstrated that fezolinetant 45 mg led to a 2.6 mean reduction in nighttime awakenings by week 12. No new safety signals were identified, with reported hepatic laboratory findings being both mild and infrequent.
The players
Fezolinetant
This is a selective neurokinin 3 receptor antagonist designed to treat vasomotor symptoms during menopause.
OPTION-VMS
This is a phase 4 clinical study that evaluated sleep outcomes and symptom management in women.
The details
The study utilized a combination of patient-reported data and wearable actigraphy to track sleep patterns. Researchers noted that women experiencing moderate to severe hot flashes are three times more likely to deal with nighttime awakenings compared to those without symptoms.
Timeline
Improvements in symptoms were observed as early as week 4.
Sleep measures showed continued progress by week 8.
The study primary endpoint was reached at week 12.
Study results were presented at the 2026 World Congress on Menopause.
The Big Picture
This study updates clinical figures previously established by research within the field presented at the 2026 World Congress on Menopause. The findings mark a continued evolution in treating vasomotor symptoms through targeted neurokinin receptor inhibition.
For women experiencing frequent nighttime awakenings due to hot flashes, this medication offers a targeted treatment to potentially restore sleep quality. Patients should consult their healthcare provider to discuss whether a neurokinin 3 receptor antagonist fits their needs.
The takeaway
Menopausal women suffering from sleep disturbances now have new data supporting the efficacy of fezolinetant in managing symptoms. Implementing consistent sleep tracking can help patients discuss specific improvements in nighttime awakenings with their doctors.
Further reading
Learn more about advancements in treatments by visiting the Women’s Health section.
Source note: This article includes information reported by Sleep Review.
Live Poll
Do you believe new non-hormonal medical treatments are effectively improving quality of life for menopausal women?
